Floatz logo

Personalized Neoantigen Mrna Tumor Vaccine

Esophageal Squamous Cell Carcinoma

Changhai HospitalvaccineN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

65 Active assets in the Esophageal Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
AstraZeneca
Phase 3BB
Eloxatin
Taiho Oncology, Inc.
Phase 3BB
Levoleucovorin
Taiho Oncology, Inc.
Phase 3BB
Irinotecan
Taiho Oncology, Inc.
Phase 2BB
Cetuximab
Hummingbird Bioscience
Phase 2B

View all 50 →

Same molecule, other indications

Personalized Neoantigen Mrna Tumor Vaccine is also rated in:

Solid Tumor MalignanciesDormant
C
Indicative ·
36 / 100
View asset →
hepatocellular carcinomaDormant
D
Indicative ·
30 / 100
View asset →
gastric adenocarcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →